William Lewis on cash runway
From Latest read on rare disease gene therapy from Insmed CEO Will Lewis · · CNBC Television
“If things fall into place next year we could be kicking off almost as many as a dozen phase three trials for multiple indications. We have a very strong cash position and that will serve us well as revenue grows from the launch of Bren Supri and Ericase continues to perform; clinical spend will pick up but we should be in good shape.”
On , William Lewis, President, Chief Executive Officer & Chairman at Insmed Incorporated, spoke about cash runway during Latest read on rare disease gene therapy from Insmed CEO Will Lewis on CNBC Television.
About William Lewis
Will Lewis, chairman and CEO of Insmed, has discussed the company’s rare disease drug pipeline and commercial performance in several recent media appearances. In January 2026, Lewis stated that Insmed has two drugs on the market: Arikayce for refractory nontuberculous mycobacterial lung disease and brensocatib for non-cystic fibrosis bronchiectasis. He said that a phase 3 trial for Arikayce, called the Encore trial, is expected to read out in March or April 2026, and that success would expand its addressable market from 30,000 to over 200,000 patients. Lewis also noted that Insmed acquired a monoclonal antibody, INS1148, to pursue indications in moderate to severe asthma and interstitial lung disease. In November 2025, Lewis said the launch of brensocatib was “very strong” in its early days, with 200 patients on the drug, and that the company’s addressable patient population could increase from roughly 250,000–280,000 to over 2.5 million by the end of the decade if pipeline programs prove successful. In June 2025, Lewis commented on positive phase 2 data for TPIP in pulmonary arterial hypertension, calling it “the best data that’s ever been put out in any clinical controlled trial ever across any medicine for this disease.” He said the company would take the data to the FDA to discuss the development path. Lewis also addressed speculation about a potential acquisition, stating that “companies are not bought or not sold, they’re bought” and that Insmed would continue to focus on driving shareholder value. In earlier remarks, Lewis discussed the high cost and long timelines of drug development, noting that the process typically takes 10 to 15 years and costs about $2 billion per drug, with a 12% success rate after phase 1. He has advocated for the removal of substantial copays for prescription medicines, saying that “if you wake up one day and find out you have cancer and someone says we have a cure but it’s $350,000, nobody has that kind of money.”